Merck & Co., Inc. news

   Watch this stock
Showing stories 1 - 10 of about 157   

Articles published

MRK 49.38 +0.79 (1.63%)
price chart
Will 2016 Be Merck & Co. Inc.'s Best Year Yet?
For example, adding Cubist Pharmaceuticals helped bolster Merck's therapeutic focus within acute hospital care products.
Merck & Co. Inc (MRK) Closes 1.29% Up on the Day for February 05
Dow Jones component Merck & Co. Inc (MRK) saw its stock move 1.29% to $49.22, representing a per-share move of $0.628, on volume of 12.13 million shares for Friday.
Blue Chip Partners Inc. Buys 501 Shares of Merck & Co., Inc. (MRK)
Merck & Co. logo Blue Chip Partners Inc. increased its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 0.9% during the fourth quarter, according to its most recent disclosure with the SEC.
BLB&B Advisors Increases Stake in Merck & Co., Inc. (MRK)  Intercooler Financial
Analytical Approach on Merck & Co. Inc. (MRK)  CWRU Observer
Merck & Co., Inc. Falters After Q4 Report
Merck & Co., Inc. (NYSE: MRK) shares are trading lower by $1.65 at $48.76 in Wednesday's session. Despite a Q4 EPS beat of $0.02 with slightly lower revenues, the Street is focusing on its lower FY 2016 outlook for EPS and revenues.
Featured Stock: Merck & Co., Inc.  CWRU Observer
Merck & Co., Inc. (NYSE:MRK) Gains Approval Of EMEND Injection From The FDA
A supplemental New Drug Application (sNDA) from Merck & Co., Inc. (NYSE:MRK) has won the approval of the US Food and Drug Administration (FDA).
Merck & Co., Inc: Emend Gets FDA Approval  Business Finance News
Most Active Healthcare Stocks- Merck & Co. (NYSE:MRK), AstraZeneca (NYSE ...  Seneca Globe
Will Merck and ImmunoGen Provide Breakthrough For Ovarian Cancer?
ImmunoGen Inc. (NASDAQ:IMGN) and Merck & Co. Inc. (NYSE:MRK) have announced that they have started clinical research collaboration for the assessment of ImmunoGen's mirvetuximab soravtansine, in combination with Merck's anti-PD-1 therapy, ...
Analyst Update: Merck & Co., Inc., Quality Systems, Inc., and Align Technology ...
Merck & Co., Inc. has shed roughly 17% of its value year-over-year, but is trading 2.2% higher at $50.26 today. Heading into the company's earnings report -- due before the open next Wednesday -- analysts are evenly split on the stock, giving seven ...
Merck & Co. Inc (MRK) Closes 1.99% Up on the Day for January 29
Dow Jones component Merck & Co. Inc (MRK) saw its stock move 1.99% to $50.18, representing a per-share move of $0.98, on volume of 9.78 million shares for Friday.
Earnings Reaction History: Merck & Co. Inc., 50.0% Follow-Through Indicator, 1 ...
Merck & Co. Inc. ( MRK ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect very active trading in the issue immediately following its quarterly earnings announcement.
Mixed Earnings Expectations For Merck And Pfizer
Pharmaceutical giants Merck & Co., Inc. (NYSE: MRK) and Pfizer Inc. (NYSE: PFE) are expected to post quarterly results this week.